Vera TherapeuticsVERA
VERA
About: Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Employees: 192
0
Funds holding %
of 7,433 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
299% more call options, than puts
Call options by funds: $29.6M | Put options by funds: $7.43M
50% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 46
0.69% more ownership
Funds ownership: 98.8% [Q1] → 99.49% (+0.69%) [Q2]
2% less capital invested
Capital invested by funds: $1.53B [Q1] → $1.49B (-$33.7M) [Q2]
5% less funds holding
Funds holding: 178 [Q1] → 169 (-9) [Q2]
13% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 40
17% less funds holding in top 10
Funds holding in top 10: 6 [Q1] → 5 (-1) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$53
135%
upside
Avg. target
$64
186%
upside
High target
$85
277%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
JP Morgan Anupam Rama | 135%upside $53 | Overweight Maintained | 7 Aug 2025 |
Scotiabank Greg Harrison | 144%upside $55 | Sector Outperform Maintained | 2 Jun 2025 |
HC Wainwright & Co. Arthur He | 277%upside $85 | Buy Maintained | 2 Jun 2025 |
Financial journalist opinion
Based on 3 articles about VERA published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) underlying 48,200 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
The Motley Fool
2 weeks ago
Vera (VERA) Q2 Net Loss Widens 127%
Vera Therapeutics (VERA 0.93%), a biotechnology company developing treatments for serious immunologic diseases, released results for the quarter on August 5, 2025. The most notable news was its widening net loss to $76.5 million, or $1.20 per share (GAAP), compared to analyst expectations for a GAAP loss of $0.82 per share.
Neutral
GlobeNewsWire
3 weeks ago
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
On track to submit a Biologics License Application (BLA) for accelerated approval of atacicept to U.S. FDA in Q4 2025; potential commercial launch in 2026 Announced positive primary endpoint results from the ongoing ORIGIN Phase 3 trial Initiated the PIONEER trial to investigate atacicept in a broader IgAN patient cohort and multiple autoimmune glomerular diseases Expected to present full primary endpoint results from the ORIGIN 3 trial at a medical congress in Q4 2025 BRISBANE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the second quarter ended June 30, 2025.
Neutral
GlobeNewsWire
1 month ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted stock units (RSUs) for 73,695 shares of Class A common stock to fifteen (15) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
MarketBeat
2 months ago
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutical companies experience when a key positive trial result is announced or an important drug receives government approval.
Neutral
GlobeNewsWire
2 months ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
2 months ago
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami Beach, FL from June 9 – 11, 2025. The management team will also participate in one-on-one investor meetings.
Neutral
GlobeNewsWire
2 months ago
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has entered into a new credit facility providing for up to $500 million of term loans with its current partner Oxford Finance LLC (“Oxford”). The new credit facility will replace Vera's existing $50 million credit facility. The initial funding of the new credit facility will be in a principal amount of $75 million and is expected to occur on June 4, 2025.
Positive
Benzinga
2 months ago
Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data
Vera Therapeutics, Inc. VERA saw its share price surge over 65% during the pre-market trading session on Monday after the company released ORIGIN Phase 3 trial data.
Positive
Reuters
2 months ago
Vera shares skyrocket as kidney disease drug succeeds in late-stage trial
Shares of Vera Therapeutics soared 82% on Monday, after the company said its experimental drug helped significantly reduce excess levels of harmful proteins in the urine of kidney disease patients in a late-stage study.
Charts implemented using Lightweight Charts™